Scientific Report 2018

EOC Academic Education, Research and Innovation Area
Viale Officina 3
6500 Bellinzona
+41(0)91 811 13 10

>> Scientific Report (pdf full version)

Rapporto Scientifico 2018

Publications Indietro

Original articles

Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfo L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica 2019;104:360-9. IF 9.090, Q1, PMID 

Banerjee S, Dafni U, Allen T, Arnold D, Curigliano GMD, Garralda E, Garassino MC, Haanen J, Hofstadter-Thalmann E, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. ESMO open 2018;3:e000422. IF 0, PMID 30273420
Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, Di Rocco A, Conconi A,Stathis A, Cavalli F, Bellei M, Cozens K, Porro E, Giovanella L, Johnson PW, Zucca E. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood 2018;132:179-86. IF 15.132, Q1, PMID 29720487
Conconi A, Zucca E, Margiotta-Casaluci G, Darling K, Hasse B, Battegay M, Staehelin C, Novak U, Schmid P, Scherrer A, Dirnhofer S, Kwee I, Nassi L, Cavalli F, Gaidano G, Bertoni F, Bernasconi E. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. Hematological oncology 2018;36:757-64. IF 3.193, Q2, PMID 30113708
Cordani M, Butera G, Dando I, Torrens-Mas M, Butturini E, Pacchiana R, Oppici E, Cavallini C, Gasperini S, Tamassia N, Nadal-Serrano M, Coan M, Rossi D, Gaidano G, Caraglia M, Mariotto S, Spizzo R, Roca P, Oliver J, Scupoli MT, Donadelli M. Mutant p53 blocks SESN1/AMPK/PGC-1alpha/UCP2 axis increasing mitochondrial O2-. production in cancer cells. British journal of cancer 2018;119:994-1008. IF 5.922, Q1, PMID 30318520
Da Ros S, Aresu L, Ferraresso S, Zorzan E, Gaudio E, Bertoni F, Dacasto M, Giantin M. Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach. PLoS One 2018;13:e0208709. IF 2.766, Q1, PMID30533020
Dal Pra A, Panje C, Zilli T, Arnold W, Brouwer K, Garcia H, Glatzer M, Gomez S, Herrera F, Kaouthar K, Papachristofilou A, Pesce G, Reuter C, Vees H, Zwahlen DR, Engeler D, Putora PM. Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice. Strahlentherapie und Onkologie 2018;194:9-16. IF 2.459, Q2, PMID 28656373
Dietrich S, Oles M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hullein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oles AK, Slabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Durig J, Ringshausen I, Zapatka M, Huber W, Zenz T. Drug-perturbation-based stratification of blood cancer. Journal of clinical investigation 2018;128:427-45. IF 13.251, Q1, PMID 29227286
Drach J, Huang H, Samoilova O, Belch A, Farber C, Bosly A, Novak J, Zaucha J, Dascalescu A, Bunworasate U, Masliak Z, Vilchevskaya K, Robak T, Pei L, Rooney B, van de Velde H,Cavalli F. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. Leukemia & lymphoma 2018;59:896-903. IF 2.644, Q2, PMID  29338540
Espeli V, Vergotte S, Dietrich PY, Pichard C, Siano M. Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy. Nutrition and cancer 2018;70:1069-74. IF 2.261, Q3, PMID30273007
Federico M, Caballero Barrigon MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Alvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, Salles G, Coiffier B. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematology 2018;5:e359-e67. IF 10.698, Q1, PMID 30078408
Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO open 2018;3:e000303. IF 0, PMID 29464112
Fiedler W, Stoeger H, Perotti A, Gastl G, Weidmann J, Dietrich B, Baumeister H, Danielczyk A, Goletz S, Salzberg M, De Dosso S. Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO open 2018;3:e000381. IF 0, PMID 30018811
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, Gomez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Jr., Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 2018;379:122-37. IF 79.258, Q1, PMID 29863451
Gamondi C, Pott M, Preston N, Payne S. Family Caregivers' Reflections on Experiences of Assisted Suicide in Switzerland: A Qualitative Interview Study. Journal of pain and symptom management 2018;55:1085-94. IF 3.249, Q1, PMID 29288877
Garcia-Escudero R, Segrelles C, Duenas M, Pombo M, Ballestin C, Alonso-Riano M, Nenclares P, Alvarez-Rodriguez R, Sanchez-Aniceto G, Ruiz-Alonso A, Lopez-Cedrun JL, Paramio JM, Lorz C. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway. Oral oncology 2018;79:55-63. IF 4.636, Q1, PMID 29598951
Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Cortes J, Vidal MJ, Hennessy B, Walshe J, Parraga KA, Ribi K, Bernhard J, Murillo SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Annals of oncology 2018;29:661-8. IF 13.926, Q1, PMID 29228091
Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI,Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foa R, Polliack A, Morabito F. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia 2018;32:1869-73. IF 10.023, Q1, PMID 29588545
Gobba S, Moccia AAGulden-Sala W, Conconi A, Diem S, Cascione L, Iacoboni G, Margiotta-Casaluci G, Aprile von Hohenstaufen KStathis A, Hitz F, Pinotti G, Gaidano G, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. Hematological oncology 2018;36:84-92. IF 3.193, Q2, PMID 28621491
Hirschmann A, Lupatsch JE, Schwenkglenks M, Panje CM, Matter-Walstra K, Espeli V, Dedes KJ, Siano M. Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral oncology 2018;87:104-10. IF 4.636, Q1, PMID 30527224
Hofstadter-Thalmann E, Dafni U, Allen T, Arnold D, Banerjee S, Curigliano GMD, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Report on the status of women occupying leadership roles in oncology. ESMO open 2018;3:e000423. IF 0, PMID 30273418
Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British journal of haematology 2018;183:755-65. IF 5.128, Q1, PMID30407629
Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Duhrsen U, Huttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol 2018;36:2845-53. IF 26.303, Q1, PMID 30125215
Kuster S, Stampf S, Gerber B, Baettig V, Weisser M, Gerull S, Medinger M, Passweg J, Schanz U, Garzoni C, Berger C, Chalandon Y, Mueller NJ, van Delden C, Neofytos D, Khanna N. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study. Transplant infectious disease 2018;20:e12981. IF 1.869, Q3, PMID 30144374
Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, Del Mastro L, Paluch-Shimon S, Loibl S, Partridge AH, Demeestere I, Azim HA, Jr., Peccatori FA. The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast 2018;42:41-9. IF 2.951, Q1, PMID 30170202
Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. J Clin Oncol 2018;36:3007-14. IF 26.303, Q1, PMID 29733771
Maffei R, Fiorcari S, Martinelli S, Benatti S, Bulgarelli J, Rizzotto L, Debbia G, Santachiara R, Rigolin GM, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Leukemia & lymphoma 2018;59:423-33. IF 2.644, Q2, PMID 28639485
Mensah AA, Cascione L, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, Stathis AZucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F. Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica2018;103:2049-58. IF 9.090, Q1, PMID 30076183
Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Loffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Fruh M, Pless M, von Moos R, John T. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. Journal of thoracic 2018;13:1784-91. IF 10.336, Q1, PMID30142389
Oza A, Kaye S, Van Tornout J, Sessa C, Gore M, Naumann RW, Hirte H, Colombo N, Chen J, Gorla S, Poondru S, Singh M, Steinberg J, Yuen G, Banerjee S. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic oncology 2018;149:275-82. IF 4.540, Q1, PMID 29454514
Pasanisi P, Bruno E, Venturelli E, Morelli D, Oliverio A, Baldassari I, Rovera F, Iula G,Taborelli M, Peissel B, Azzolini J, Manoukian S. A Dietary Intervention to Lower Serum Levels of IGF-I in BRCA Mutation Carriers. Cancers 2018;10. IF 5.326, Q1, PMID 30181513
Passweg JR, Baldomero H, Ansari M, Baerlocher GM, Bargetzi M, Chalandon Y, Duchosal MA, Gerull S, Gungor T, Halter JP, Heim D, Hess U, Leibundgut K, Masouridi-Levrat S, Muller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, For The Swiss Blood Stem Cell Transplantation Group S. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016. Swiss medical weekly 2018;148:w14589. IF 1.928, Q2, PMID 29493715
Pautex S, Gamondi C, Philippin Y, Gremaud G, Herrmann F, Camartin C, Vayne-Bossert P. Advance directives and end-of-life decisions in Switzerland: role of patients, relatives and health professionals. BMJ supportive & palliative care 2018;8:475-84. IF 2.385, Q2, PMID26338849
Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Chih-Hsin Yang J, Lorence RM, Carriere P, Cseh A, Chang GC. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. Journal of thoracic oncology 2018;13:1897-905. IF 10.336, Q1, PMID 30096481
Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foa R. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Annals of oncology 2018;29:966-72. IF 13.926, Q1, PMID 29365086
Restelli V, Lupi M, Vagni M, Chila R, Bertoni F, Damia G, Carrassa L. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. Targeted oncology 2018;13:235-45. IF 3.877, Q2, PMID 29441438
Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G, Zanagnolo V, Del Grande M, Colombo N, Bellomi M. Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. European radiology 2018;28:4849-59. IF 4.027, Q1, PMID 29737390
Rizzo S, Femia M, Radice D, Del Grande M, Franchi D, Origgi D, Buscarino V, Mauro A, Bellomi M. Evaluation of deep myometrial invasion in endometrial cancer patients: is dual-energy CT an option? Radiologia medica 2018;123:13-9. IF 1.819, Q3, PMID 28924863
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncology 2018;19:1449-58. IF 36.418, Q1, PMID 30348538
Rossi L, Biagioni C, McCartney A, Moretti E, Pestrin M, Sanna G, Risi E, Malorni L, A DIL, Biganzoli L. Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. Anticancer research 2018;38:4839-45. IF 1.865, Q4, PMID 30061257
Rothenbuhler C, Held U, Manz MG, Schanz U, Gerber B. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia. Hematological oncology 2018;36:471-80. IF 3.193, Q2, PMID 29431860
Siano M, Espeli V, Mach N, Bossi P, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Oral oncology 2018;82:144-51. IF 4.636, Q1, PMID29909889
Siano M, Jarisch N, Joerger M, Espeli V. Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer. Anticancer research 2018;38:3725-9. IF 1.865, Q4, PMID 29848734
Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AAStathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber BBertoni FGhielmini MStussi G, Santoro A, Cavalli FZucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018;131:2413-25. IF 15.132, Q1, PMID 29449275
Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Investigational new drugs 2018;36:869-76. IF 3.502, Q1, PMID 29453628
Strickler N, Balabanov S, Casauro K, Schanz U, Manz MG, Gerber B. Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase. Leukemia & lymphoma 2018;59:855-62. IF 2.644, Q2, PMID28728499
Tarantelli C, Bernasconi E, Gaudio E, Cascione L, Restelli V, Arribas AJ, Spriano F, Rinaldi A, Mensah AA, Kwee I, Ponzoni MMD, Zucca E, Carrassa L, Riveiro ME, Rezai K, Stathis A, Cvitkovic E, Bertoni F. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO open 2018;3:e000387. IF 0, PMID 30305939 
Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A,Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi DStathis AStussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical cancer research 2018;24:120-9. IF 10.199, Q1, PMID 29066507
Valli MCima SFanti PMuoio B, Vanetti A, Azinwi CNYordanov KMartucci FPesce GA, Canonica C, Richetti A. The role of radiotherapy in elderly women with early-stage breast cancer treated with breast conserving surgery. Tumori 2018:300891618792465. IF 1.304, Q4, PMID 30145939
van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootscholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, Voest EE. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids. Cancer chemotherapy and pharmacology 2018;81:911-21. IF 2.808, Q2, PMID 29574584
Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecologic oncology 2018;150:471-7. IF 4.540, Q1, PMID 30060963
Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Annals of oncology 2018;29:1926-31. IF 13.926, Q1, PMID30010775
von Moos R, Koeberle D, Schacher S, Hayoz S, Winterhalder RC, Roth A, Bodoky G, Samaras P, Berger MD, Rauch D, Saletti P, Plasswilm L, Zwahlen D, Meier UR, Yan P, Izzo P, Klingbiel D, Bartschi D, Zaugg K. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). European journal of cancer 2018;89:82-9. IF 7.191, Q1, PMID 29241084
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanovic N, Cmiljanovic V, Stumm M, Dimitrijevic S, Herrmann R, Pretre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). European journal of cancer 2018;96:6-16. IF 7.191, Q1, PMID 29660598
Widmer F, Balabanov S, Soldini D, Samaras P, Gerber B, Manz MG, Goede JS. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience. Annals of hematology 2018;97:277-87. IF 2.845, Q2, PMID 29147847
Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Annals of oncology 2018;29:707-14. IF 13.926, Q1, PMID29253068
Bertoni FRossi DZucca E. Recent advances in understanding the biology of marginal zone lymphoma. F1000Research 2018;7:406. IF 0, PMID 29657712
Broekman KE, Jalving M, van Tinteren H, Sessa C, Reyners AKL. Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores. Cancer treatment reviews 2018;69:233-42. IF 8.122, Q1, PMID 30098485
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortes J, Curigliano G, Dieras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of oncology 2018;29:1634-57. IF 13.926, Q1, PMID30032243
Condoluci ARossi DZucca E, Cavalli F. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma. Current oncology reports 2018;20:79. IF 3.122, Q3, PMID 30132080
Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert review of anticancer therapy 2018;18:1101-12. IF 2.347, Q3, PMID 30188738
Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia 2018;32:1070-80. IF 10.023, Q1, PMID 29467486
Minoia CZucca EConconi A. Novel acquisitions on biology and management of transformed follicular lymphoma. Hematological oncology 2018;36:617-23. IF 3.193, Q2, PMID29602222
Minotti G, Han H, Cattan V, Egorov A, Bertoni F. Pixantrone: novel mode of action and clinical readouts. Expert review of hematology 2018;11:587-96. IF 1.937, Q3, PMID 29912583
Moccia AA, Thieblemont C. Curing diffuse large B-cell lymphomas in elderly patients. European journal of internal medicine 2018;58:14-21. IF 3.282, Q1, PMID 30472108
Muoio B, Giovanella L, Treglia G. Recent Developments of 18F-FET PET in Neuro-oncology. Current medicinal chemistry 2018;25:3061-73. IF 3.469, Q2, PMID 29173147
Muoio BPascale MRoggero E. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature. International journal of biological markers 2018;33:10-21. IF 1.499, Q4, PMID 28885659
Omlin A, Spahn M, Beyer J, Eberli D, Gillessen S, Jochum W, Kueng M, Nitzsche E, Rentsch CA, Roggero E, Schmid HP, Stenner F, Templeton AJ, Wild D, Wyler S, Zwahlen D, Cathomas R. Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation. Praxis 2018;107:1043-51. IF 0, PMID 30227804
Rizzo S, Femia M, Buscarino V, Franchi D, Garbi A, Zanagnolo V, Del Grande M, Manganaro L, Alessi S, Giannitto C, Ruju F, Bellomi M. Endometrial cancer: an overview of novelties in treatment and related imaging keypoints for local staging. Cancer imaging 2018;18:45. IF 3.016, Q2, PMID 30514387
Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood 2018;131:2761-72. IF 15.132, Q1, PMID 29692342
Rossi LPagani O. The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer. Journal of womens health 2018;27:466-75. IF 2.097, Q1, PMID28926289
Saletti PSanna P, Gabutti L, Ghielmini M. Choosing wisely in oncology: necessity and obstacles. ESMO open 2018;3:e000382. IF 0, PMID 30018817
Saletti P, Zaniboni A. Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. Journal of gastrointestinal oncology 2018;9:377-89. IF 0, PMID 29755778
Stathis ABertoni F. BET Proteins as Targets for Anticancer Treatment. Cancer discovery 2018;8:24-36. IF 24.373, Q1, PMID 29263030
Stathis A, Iasonos A, Seymour JF, Thieblemont C, Ribrag V, Zucca E, Younes A. Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas. Clinical cancer research 2018;24:2993-8. IF 10.199, Q1, PMID 29535129
Suter MB, Pagani O. Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. Therapeutic advances in medical oncology 2018;10:1758835918776923. IF 6.238, Q1, PMID 29977348
Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology 2018;5:e563-e98. IF 10.698, Q1, PMID 29907552
Case reports
Innocenti I, Rossi D, Trape G, Autore F, Larocca LM, Gomes V, Cerri M, Falcucci P, Sica S, Gaidano G, Laurenti L. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematological oncology 2018;36:600-3. IF 3.193, Q2, PMID 29484684
Mangas C, Espeli V, Blum R. A Case of Eruptive Disseminated Porokeratosis in a Cancer Patient after Trastuzumab and Exemestane Treatment: Cancer Related or Drug Induced Phenomenon? Actas dermo-sifiliograficas 2018;109:559-60. IF 0, PMID 29221608
Editorials or letters or comments or study protocols
Condoluci ARossi D. Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association? Haematologica 2018;103:751-2. IF 9.090, Q1, PMID 29712819
D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R. NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. British journal of haematology 2018;182:597-602. IF 5.128, Q1, PMID 28699643
Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thurlimann B, Andre F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC,Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Annals of oncology 2018;29:281-2. IF 13.926, Q1, PMID 29045519
Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foa R, Morabito F. Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. American journal of hematology 2018;93:E35-e7. IF 5.303, Q1, PMID29098721
Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foa R, Morabito F. Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. European journal of haematology 2018;101:575-708. IF 2.595, Q3, PMID 30039576
Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch EServida P, Bertoni F, Zucca EGhielmini M, Cortelezzi A,Cavalli FStussi G, Baldini L, Rossi D, Neri A. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica 2018;103:e245-e8. IF 9.090, Q1, PMID 29472358
Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E, Monitillo L, Cerri M, Ruggeri M, Omede P, Deambrogi C, De Paoli L, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S. Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. British journal of haematology 2018;181:693-5. IF 5.128, Q1, PMID 28369711
Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foa R. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia 2018;32:543-6. IF 10.023, Q1, PMID 28924243
Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, Di Renzo N, Molica S, Angrilli F, Chiarenza A, Cutrona G, Chaffee KG, Parikh SA, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Cortelezzi A, Gaidano G, Di Raimondo F, Fais F, Foa R, Neri A, Ferrarini M. Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American journal of hematology 2018;93:E216-e9. IF 5.303, Q1, PMID29984867
Noseda R, Magro L, Stathis A, Ceschi A. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet 2018;392:383-4. IF 53.254, Q1, PMID 30102169
Restelli V, Vagni M, Arribas AJ, Bertoni F, Damia G, Carrassa L. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation. British journal of haematology 2018;181:129-33. IF 5.128, Q1, PMID 28025833
Rossi DZucca E. Foreword. European journal of internal medicine 2018;58:1. IF 3.282, Q1, PMID 30501918
Rossi L. The Open Issues Regarding Cyclin-Dependent Kinase 4/6 Inhibitors in the Management of Advanced Breast Cancer. Journal of breast cancer 2018;21:468-70. IF 2.456, Q3, PMID 30607170